Rein Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Austin, TX
RNTX chart
What traders are saying about $RNTX
Latest postsRein Therapeutics, Inc. news
- Maxim Group Maintains Rein Therapeutics(RNTX.US) With Buy Rating, Maintains Target Price $4
Moomoo ·
- Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
Yahoo Finance ·
- Here's Why You Should Add RNTX Stock to Your Portfolio Now
Yahoo Finance ·
- Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Yahoo Finance ·
- Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Yahoo Finance ·
- Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
Yahoo Finance ·
- Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
Yahoo Finance ·
- All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
Yahoo Finance ·
- Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Yahoo Finance ·
- Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
Yahoo Finance ·
- Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
Yahoo Finance ·
- Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
Yahoo Finance ·
Rein Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net income | -$49.9M | -$62.9M | -$15.7M | -$27.3M |
| Diluted EPS | $-1.96 | $-3.51 | $-3.42 | $-6.02 |
| Total assets (year end) | $24.2M | $62.2M | $106.0M | $22.0M |
| Cash and equivalents (year end) | $3.2M | $12.9M | $17.3M | $5.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Rein Therapeutics, Inc.
- Ticker
- RNTX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Austin, TX
- Fiscal year end
- December 31
- SEC CIK
- 1420565
- Former names
- Aileron Therapeutics, Inc., AILERON THERAPEUTICS INC
Frequently asked questions
What exchange is Rein Therapeutics, Inc. listed on?
Rein Therapeutics, Inc. trades on the Nasdaq under the ticker symbol RNTX.
What industry is Rein Therapeutics, Inc. in?
Rein Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Rein Therapeutics, Inc. headquartered?
Rein Therapeutics, Inc.'s business address on file with the SEC is in Austin, TX.
When does Rein Therapeutics, Inc.'s fiscal year end?
Rein Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Rein Therapeutics, Inc. report?
Rein Therapeutics, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.